OBJECTIVES: Transcatheter aortic valve implantation (TAVI) has become an established procedure in patients with aortic stenosis and high surgical risk. Experience with first-generation transcatheter heart valves (THVs) is broad but limitations, e.g. paravalvular regurgitation, have been demonstrated. Much hope rests on the recently Conformité Européenne mark approved next-generation devices to improve results in these patients. However, apart from the initial approval studies, clinical data with these new devices are still scarce. We aimed to assess short-term outcomes of 200 consecutive patients who underwent transapical TAVI with next-generation THV at our institution.
INTRODUCTION
Transcatheter aortic valve implantation (TAVI) has become an established procedure in patients with severe aortic stenosis considered inoperable or at high surgical risk [1] . After the first-in-man implantation of an aortic transcatheter heart valve (THV) in 2002, and following CE mark (Conformité Européenne) approval for the Edwards Sapien (Edwards Lifesciences, Irvine, CA, USA) and CoreValve Revalving System (Medtronic Inc., Minneapolis, MN, USA) in 2007, broad experience has been gained with these devices. Due to the early adoption in Europe, several large multicentre registries were able to reflect a 'real-world' perspective with good mid-term results [2] [3] [4] . In addition, the PARTNER trial demonstrated superior outcomes in inoperable patients undergoing TAVI over conservative therapy (cohort B) [5] and non-inferiority to surgical aortic valve replacement in those considered high surgical risk [6, 7] . However, several limitations after implantation of these first-generation devices became obvious, often related to suboptimal positioning, implantation and sealing of the THV within the aortic annulus, resulting in a relevant incidence of paravalvular regurgitation, negatively affecting mid-term survival [6] .
In 2011 and 2012, three Nitinol-based second-generation transapical THV received CE mark after promising results in the initial approval studies (Fig. 1 ). Several features of these prostheses aim to reduce the incidence of paravalvular regurgitation. Overall, these strategies comprise controlled positioning and release of the valve, including mechanisms to resheath and reposition the device, tactile feedback and improved annular sealing. The JenaValve ( JenaValve Technology GmbH, Munich, Germany) transapical THV contains a mechanism that clips the prosthesis to the native aortic valve leaflets and positioning feelers to guide anatomically correct positioning within the aortic annulus [8, 9] . The Symetis Acurate (Symetis SA, Ecublens, Switzerland) features three stabilization arches, designed to ease axial alignment of the valve within the ascending aorta and accurate placement of the valve with radio-opaque markers at the valve stent for anatomically correct orientation [10, 11] . The Medtronic Engager (Medtronic, Minneapolis, MN, USA) consists of a Nitinol frame with three support arms to accommodate the native aortic sinuses for anatomically correct implantation and a supra-annular position of the valve [12] [13] [14] . To adapt for asymmetric annular calcifications and minimize paravalvular leakage, a sealing skirt has been added to the lower part of the Nitinol stents of the Engager and Symetis prostheses.
Initial experience with these transapical second-generation devices was encouraging with good haemodynamic function and low rates of paravalvular regurgitation [8, 11, 12] . However, apart from the approval studies, real-world clinical data with these second-generation valves is still scarce. To further evaluate periand postprocedural results with these new devices, we retrospectively analysed the outcomes of 200 consecutive patients who underwent transapical TAVI with Engager, JenaValve or Symetis THV at our institution.
METHODS

Patient population
From March 2011 through August 2013, 200 consecutive patients underwent transapical TAVI with next-generation devices for severe aortic valve disease at our institution (31.3% of total TAVI procedures in this time period). This included the early learning experience with these devices and 101 of the 200 patients were part of CE mark approval studies; the remaining 99 patients underwent implantation after CE mark approval was granted. All patients presented with severe comorbidities precluding them from surgical aortic valve replacement as determined by an interdisciplinary heart team of interventional cardiologists and cardiovascular surgeons. Preprocedural workup included transoesophageal echocardiography, coronary angiography and contrast-enhanced electrocardiogram-gated multislice computed tomography to evaluate access options, annular size, aortic root geometry and predict c-arm angulation. The heart team selected the specific THV for each patient on an individual basis without preference for one device or the other due to the lack of available clinical data. Exempt from this strategy were 9 patients presenting with severe non-calcified aortic regurgitation who underwent TAVI with the JenaValve THV due to its specific stent design.
Procedure
TAVI was performed in a hybrid suite under general anaesthesia in all cases by an interdisciplinary heart team of cardiac surgeons, interventional cardiologists and anaesthesiologists. A prepared heart-lung machine was available in the hybrid suite for safety reasons. Transapical access was gained in the usual fashion and implantation of one of the three second-generation devices was performed, as previously described [9, 10, 14] . After balloon valvuloplasty (balloon size 1 mm smaller than the native aortic annulus) under rapid ventricular pacing, actual implantation of the second-generation device was performed in the beating heart, sparing the patient a second run of rapid ventricular pacing.
Clinical follow-up, data management and analysis All relevant baseline, procedural and follow-up data were collected and entered into a dedicated database. Median follow-up duration was 219 (inter-quartile range 43-405) days. Residual aortic regurgitation was evaluated by transoesophageal echocardiography at the end of the procedure. Outcomes were analysed in accordance with the updated standardized end points defined by the Valve Academic Research Consortium (VARC) [15] for the overall cohort and compared for the three groups (Engager, JenaValve, Symetis) according to the THV selected for implantation.
Categorical data are presented as counts ( percentages); they were compared with the χ 2 test. Continuous data are presented as means ± 1 standard deviation or median (interquartile range) in case of skewed distribution; they were compared using analysis of variance or Kruskal-Wallis test. Improvement in valve function was evaluated with a paired t-test. Event rates are represented using Kaplan-Meier estimates and compared with a log-rank test. P-values are reported without correction for multiple testing. The level of statistical significance was set to two-tailed P < 0.05. Statistical analysis was performed using SPSS version 20 and GraphPad Prism version 6.0.
Ethics
All patients were fully informed about the procedure and signed written consent forms.
RESULTS
Baseline characteristics
Mean patient age was 80.5 ± 6.7 years, and patients presented with a substantial prevalence of comorbidities and prior cardiac operations, yielding a logistic EuroSCORE of 20.2 ± 16.5% and a Society of Thoracic Surgeon predicted risk of operative mortality of 6.6 ± 5.3% (Table 1 ). Distinct differences between the three groups were present with regard to several baseline variables, including the presence of peripheral vascular disease, prior percutaneous coronary intervention (PCI), mean transvalvular aortic gradients and effective orifice areas.
Periprocedural results
Detailed periprocedural results are given in Table 2 . Native aortic annulus diameters differed between the groups due to the different availability of THV sizes and recommended target size ranges for implantation by the manufacturers. Median procedure time was 80 min with 6.3 min of fluoroscopy and 140 ml of contrast agent, overall. Duration of procedure, fluoroscopy and use of contrast agent were highest in JenaValve patients. Post-dilatation for residual paravalvular aortic regurgitation or incomplete stent expansion was performed frequently (43.0% overall). The overall rate of transcatheter valve-in-valve implantation using an Edwards Sapien XT was 3.0%. It was performed for residual paravalvular regurgitation in 3 patients after implantation of a Symetis THV, in 2 of whom the prosthesis was implanted too low towards the leftventricular outflow tract. Supra-annular dislocation necessitated valve-in-valve procedures in 3 patients after implantation of a JenaValve THV. In addition, 1 patient was readmitted with symptomatic aortic stenosis and increasing transvalvular gradients (mean gradient 37 mmHg) 5 months after implantation of a JenaValve and underwent valve-in-valve implantation with a Sapien XT device with good haemodynamic results thereafter. Conversion to surgical aortic valve replacement was performed in 1 patient due to dislocation of the JenaValve prosthesis and additional apical bleeding. One case of an aortic dissection localized at the sinus after implantation of a JenaValve was managed conservatively without any further complications. Valve function improved significantly with an increase in effective orifice areas form 0.8 ± 0.4 to 1.8 ± 0.3 cm 2 and a reduction in mean transvalvalvular gradient from 34.0 ± 17.0 to 11.2 ± 5.4 mmHg at discharge (both P < 0.001). Paravalvular regurgitation was none or trace in 70.3%, Grade 1 in 26.1% and Grade 2 in 3.5% of patients. No aortic regurgitation > Grade 2 was present after implantation ( Fig. 2A) . Overall, New York Heart Association (NYHA) classification improved with 72.8% of patients in NYHA functional classes I and II at 30 days, compared with 10.5% at baseline (Fig. 2B) .
Standardized end points and outcomes
Data on standardized end points are detailed in Table 3 . Major access site complications, mostly related to bleeding from the apex or thoracic wall occurred in 6.5% of patients. Major and lifethreatening bleeding occurred in a total of 26 patients (13%). Severe acute kidney injury, defined according to VARC, was a rare event in 5 patients (2.5%). No cases of intraprocedural coronary obstruction occurred but one myocardial infarction was observed in a patient with diffuse pre-existing coronary artery disease without therapeutic options. The patient experienced low-cardiac output during the procedure with significant increase in cardiac biomarkers and persistent haemodynamic insufficiency, requiring implantation of extracorporeal membrane oxygenation before implantation of an Engager THV. Major cerebrovascular events occurred in 3 patients (1.5%), only 1 of whom experienced a thromboembolic stroke during rehabilitation while the other 2 patients suffered from hypoxic brain injury after temporary lowcardiac output. A pacemaker implantation rate of 30% in the Engager patients may have contributed to a longer in-hospital length of stay (Tables 2 and 3) . A new-onset complete heart block occurred in 16 patients (8%). The remaining 25 patients scheduled for implantation of a permanent pacemaker suffered from symptomatic bradyarrhythmia, left-bundle-branch block and concomitant first-degree atrioventricular block, bisfascicular block or sick sinus syndrome. Composite end points demonstrated device success in 90% and combined 30-day safety in 17%. The latter was mostly attributed to the incidence of bleeding events.
All-cause and cardiac mortality was 8.5 and 5.5% at 30 days. Cumulative all-cause mortality was 26.1% at 1 year with better survival in Symetis patients (P = 0.047). Cumulative cardiac mortality was 15.6% at 1 year without statistically significant differences between the three groups.
DISCUSSION
The current study comprises a large single-centre experience with three different next-generation THV in patients at high surgical risk suffering from severe aortic valve disease. After initial feasibility and CE mark approval studies [8, 11, 12] , this report confirms positive clinical results and low periprocedural complication rates after implantation of the Medtronic Engager, JenaValve or Symetis Acurate THV. Echocardiographic measurements confirmed adequate haemodynamic function with a significant improvement in effective orifice area, a reduction in transvalvular gradients and a low rate of residual leakage after TAVI with any of the three devices.
The incidence of residual paravalvular leakage after implantation of first-generation THV was substantial with some residual [20] . Growing evidence confirms that more-than-mild paravalvular regurgitation is associated with excess mortality during follow-up [6, [21] [22] [23] and all measures should be taken to further reduce the burden of residual aortic regurgitation after TAVI. Several characteristics of the new THV address this issue, such as enhanced positioning accuracy, controlled and anatomically correct implantation and improved sealing even in eccentric annular calcifications. With these concepts, no more-than-mild paravalvular regurgitation was observed in our series. However, a significant rate of post-dilatation was required, possibly due to lower radial strength of the Nitinolbased stents compared with balloon-expandable THV. Although no immediate complications were observed (e.g. annular rupture), post-dilatation under rapid ventricular pacing may have in part offset the initial advantage of omitting rapid pacing during valve implantation. Possibly due to the stent design of the Engager THV sealing paravalvular leakage with a skirt covering the lower stent part, a trend towards an increased incidence of conduction disorders, when compared with the other two THV, was observed and implantation of a permanent pacemaker was performed in 30% of patients implanted with an Engager THV. The incidence of newonset conduction disturbances requiring a pacemaker implantation was lowest in JenaValve patients. Whether the absence of a sealing skirt protruding into the left-ventricular outflow tract in this THV was associated with this finding remains to be determined. Although an adverse impact of permanent pacemaker implantation on survival after TAVI has not been demonstrated [24] , the influence of chronic (often times ventricular) pacing in these patients needs to be further evaluated during long-term follow-up. Cardiac mortality including unknown causes of death. b Pre-existing diffuse coronary artery disease without therapeutic options and persistent low-cardiac output during the procedure requiring ECMO implantation with a significant increase in cardiac biomarkers. Overall, the rate of periprocedural complications according to the updated VARC definitions was low despite the early learning curve with these next-generation THV and a further reduction in safety events may be anticipated. No significant differences were observed between the three groups. A trend towards a higher rate of the composite 30-day safety end point in JenaValve patients was due to a higher incidence of bleeding events in these patients. However, major access site complications were not different between groups. Since the VARC definition of bleeding events include the amount of packed red blood cells transfused [15] , baseline anaemia may have largely triggered these events, leading to an overestimation of clinically relevant bleeding.
As part of the 200 consecutive patients, 9 patients underwent implantation of a JenaValve THV for pure aortic regurgitation, as previously described [25] . Due to its unique clip mechanism, fixation of the stent within the aortic annulus is feasible even in the absence of annular calcifications and JenaValve has recently received CE mark for this new indication. A higher use of contrast agent, fluoroscopy and procedure time in patients undergoing implantation of a JenaValve THV may relate to a more complex visualization needed to ensure that all three feelers are caught within the aortic sinuses. However, this did not relate into a higher incidence of acute kidney injury or differences in device success.
Survival at 30 days and 1 year compares favourably with other data from first-and second-generation transapical TAVI [4-6, 8, 11, 12, 19] . Whether superior haemodynamic valve performance of the next-generation devices, the operator's growing experience, improved patient selection or advanced imaging, among other factors, contributed most to these results needs to be evaluated in future studies. Despite comparable all-cause and cardiac mortality at 30 days, a significant difference in cumulative all-cause mortality was observed at 1 year between the groups. However, cumulative cardiac mortality at 1 year was not different, suggesting that the differences in all-cause mortality were most probably related to disparities at baseline or factors unrelated to the procedure or THV.
Major limitations of the study include its single-centre observational character, yielding differences in baseline characteristics. A non-randomized assignment of the three second-generation THV impedes direct comparison of the short-term results achieved with the transapical Engager, JenaValve or Symetis THV and makes it susceptible to confounders.
To date, no scientific evidence exists with regard to the optimal choice for a particular prosthesis or annulus morphology. Calcification patterns, root anatomy and mode of valve failure may be critical factors in this regard. All three transapical next-generation THV have demonstrated positive haemodynamic results with low periprocedural complication rates. However, long-term durability of these new valve prostheses remains to be demonstrated. With next-generation devices now entering the trans-femoral and transaortic arena and apical closure devices already taking the transapical approach towards a percutaneous stage, further improvement in haemodynamic function, ease of implantation and procedural success can be anticipated.
APPENDIX. CONFERENCE DISSCUSSION
Dr D. Wendt (Essen, Germany): In total, I have four questions for you; one very provocative. My first question has been answered partly with your presentation. I found that within the paper, the pacemaker implantation rate was pretty high, overall about 30%. So maybe you can give us some details about that.
And the next question is about the major bleeding. Within the paper, the major bleeding rate was reported at about 14% with more than 17% in the JenaValve group, so maybe you can elaborate a little bit on that: Is this related to the device size or to your surgical strategy?
The next question concerns the balloon aortic valvuloplasty. All these second-generation valves can be implanted without balloon valvuloplasty; however, this is only true for 60% of your patients, since in 40% you performed a redilatation after implantation due to insufficiency. So you need rapid pacing, again, for reballooning in 40%.
And my last question is a little bit provocative: Do we really need all these new devices? Maybe you can give us your insight. So which valve fits which patients, since currently there are many new valves coming out by AorTech and the Portico system and new transfemoral systems by Symetis. So which patient profits from which valve?
Dr Treede: Starting with the first question, pacemaker rates, I also have to confess that in our hospital we have a quite liberal policy in the decision for implanting pacemakers because we had some bad experiences with patients who had late onset of AV block 3; frankly, we just found patients dead on the wards on day 5 and we did not want to see this anymore. So we have probably a more liberal attitude to implanting pacemakers than other hospitals have.
But yes, of course, the pacemaker rate with these new devices may be a little bit higher than with earlier-generation devices. It is maybe the payoff for the reduction in PVL. So this is what you get; this is what you pay.
I personally have not seen a study yet that has proven a bad influence of pacemaker implantation on long-term outcome. So from that perspective, I feel safe in implanting rather one pacemaker too many than one too few. And this may be the reason why we, in this particular study, have seen slightly higher pacemaker rates.
The second question was regarding the balloon dilatation, or actually about rapid pacing during the implantation. So, of course, for all these three valve types, you do not need rapid pacing to do the implantation. I think this is definitely an advantage, not only because of the balloon dilatation, but also because you can take your time during implant, and you can really implant the valves in a very thorough and very controlled way because you are not under time constraints, because when the rapid pacing is going on, the pressure drops.
Then, since it is nitinol, which is the basic concept that stands behind all the valve types, there is a certain risk for post-dilatation, of course, because nitinol per se does not have the same strength as the balloon expandable valve has. So, yes, in 40% of patients, we see the need for post-dilatation. It is clearly linked to the degree of calcification. So if you have a heavily calcified valve, you may say already, before starting the implantation, that this patient would be very prone to post-dilatation; if there is less calcium on the valve, then you can also say there is probably no need for it. So it is basically more or less dependent on the degree of calcification.
Do we need all these valve types? It is actually a good question. I think it depends very much on the volume of your centre. If you have a small-volume centre, there is no need to have all of them on board. Definitely, you just pick the one you feel most comfortable with, and if there is one that has the most reliable data in your mind, then you go from there.
Since we have the opportunity to have a very large centre, I really am very happy that I have access to all these different valve types. I would definitely not use all of them, but I would definitely use the three of them further on, also to find out which one is probably better suited for which type of calcification.
Dr Wendt: And concerning the bleeding rate? Dr Treede: The bleeding rate is reported according to VARC 2 definitions. So in a surgical procedure, two units of blood are already reported as a major bleeding. You have to have this in mind. And some patients show up with very low Hb levels. What we do not do is cosmetics; give them blood units before bringing them to the OR. We really prefer to see what happens afterwards. Do they feel good? Do they recover well? If they don't recover so well and have a low Hb rate, then I would rather give blood units and have another tick in the box on the major-bleeding side, according to VARC 2 definitions, but have the patients early on their feet again. So you always have to ask: Is it really true bleeding? Is it really a disastrous apical access, or is it something different? Sometimes it is just bleeding from the groin puncture for the implantation of the pigtails. I cannot say that the valve types themselves have any differences in terms of apical bleeding. So this slightly larger JenaValve size is not linked to any higher risk for bleeding on the apical side.
Dr N. Moat (London, UK) Just one last brief question: In the Symetis and the Jena groups, you've got about a 5% instance of valve-in-valve which in the abstract is due to valve migration. Can you comment on that? Do you think that it is a learning curve, or do you think that it is device-specific? Dr Treede: I think it is a learning curve, actually. And it's in favour of those two in comparison to the Engager, because the Engager, mostly at this part of our experience, has been implemented within the study. So it was a singleoperator procedure, while the others have already been in routine use. And we have at least three, sometimes four surgeons who do implantations at our side. So that's a learning curve not only for one person, but for four persons.
And then you see, of course, more problems that you would not see with other valve types. I don't think it's a conceptual problem of one or the other.
